Cargando…

Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment

BACKGROUND: Hyperuricemia is common during tuberculosis (TB) treatment, especially in association with pyrazinamide (PZA). This study investigated the relationship between major adverse cardiovascular events (MACEs) and hyperuricemia during TB treatment. METHODS: We conducted a single-center retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Hong-Joon, Yoon, Joon-Young, Na, Young-Ok, Lee, Jae-Kyeong, Kho, Bo Gun, Kim, Tae-Ok, Kim, Yu-Il, Lim, Sung-Chul, Jeong, Sae-Hee, Kwon, Yong-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653473/
https://www.ncbi.nlm.nih.gov/pubmed/37972037
http://dx.doi.org/10.1371/journal.pone.0294490
_version_ 1785147784339390464
author Shin, Hong-Joon
Yoon, Joon-Young
Na, Young-Ok
Lee, Jae-Kyeong
Kho, Bo Gun
Kim, Tae-Ok
Kim, Yu-Il
Lim, Sung-Chul
Jeong, Sae-Hee
Kwon, Yong-Soo
author_facet Shin, Hong-Joon
Yoon, Joon-Young
Na, Young-Ok
Lee, Jae-Kyeong
Kho, Bo Gun
Kim, Tae-Ok
Kim, Yu-Il
Lim, Sung-Chul
Jeong, Sae-Hee
Kwon, Yong-Soo
author_sort Shin, Hong-Joon
collection PubMed
description BACKGROUND: Hyperuricemia is common during tuberculosis (TB) treatment, especially in association with pyrazinamide (PZA). This study investigated the relationship between major adverse cardiovascular events (MACEs) and hyperuricemia during TB treatment. METHODS: We conducted a single-center retrospective cohort study. From January 2010 through June 2017, we assessed all consecutive TB patients at Chonnam National University Hospital in South Korea. Hyperuricemia was defined as serum uric acid levels exceeding 7.0 mg/dL (men) and 6.0 mg/dL (women). RESULTS: Of the 1,143 patients included, PZA was administered to 1,081 (94.6%), and hyperuricemia was detected in 941 (82.3%). Eight patients experienced MACEs. Multivariate analysis using logistic regression indicated that prior ischemic heart disease was associated with MACE development (OR,14.087; 95% CI,3.304–60.061; P < 0.000), while hyperuricemia was not (OR, 1.505; 95% CI, 0.184–12.299; P = 0.703). For patients without drug-resistant TB, the absence of hyperuricemia was associated with higher mortality (OR, 2.609; 95% CI, 1.066–6.389; P = 0.036), whereas hyperuricemia was associated with less worse outcomes (OR,0.316; 95% CI,0.173–0.576; P < 0.000). CONCLUSIONS: Although most patients treated with PZA developed hyperuricemia, it was not associated with MACE development. Hyperuricemia during TB treatment was associated with better outcomes, possibly due to consistent adherence to TB treatment.
format Online
Article
Text
id pubmed-10653473
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-106534732023-11-16 Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment Shin, Hong-Joon Yoon, Joon-Young Na, Young-Ok Lee, Jae-Kyeong Kho, Bo Gun Kim, Tae-Ok Kim, Yu-Il Lim, Sung-Chul Jeong, Sae-Hee Kwon, Yong-Soo PLoS One Research Article BACKGROUND: Hyperuricemia is common during tuberculosis (TB) treatment, especially in association with pyrazinamide (PZA). This study investigated the relationship between major adverse cardiovascular events (MACEs) and hyperuricemia during TB treatment. METHODS: We conducted a single-center retrospective cohort study. From January 2010 through June 2017, we assessed all consecutive TB patients at Chonnam National University Hospital in South Korea. Hyperuricemia was defined as serum uric acid levels exceeding 7.0 mg/dL (men) and 6.0 mg/dL (women). RESULTS: Of the 1,143 patients included, PZA was administered to 1,081 (94.6%), and hyperuricemia was detected in 941 (82.3%). Eight patients experienced MACEs. Multivariate analysis using logistic regression indicated that prior ischemic heart disease was associated with MACE development (OR,14.087; 95% CI,3.304–60.061; P < 0.000), while hyperuricemia was not (OR, 1.505; 95% CI, 0.184–12.299; P = 0.703). For patients without drug-resistant TB, the absence of hyperuricemia was associated with higher mortality (OR, 2.609; 95% CI, 1.066–6.389; P = 0.036), whereas hyperuricemia was associated with less worse outcomes (OR,0.316; 95% CI,0.173–0.576; P < 0.000). CONCLUSIONS: Although most patients treated with PZA developed hyperuricemia, it was not associated with MACE development. Hyperuricemia during TB treatment was associated with better outcomes, possibly due to consistent adherence to TB treatment. Public Library of Science 2023-11-16 /pmc/articles/PMC10653473/ /pubmed/37972037 http://dx.doi.org/10.1371/journal.pone.0294490 Text en © 2023 Shin et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Shin, Hong-Joon
Yoon, Joon-Young
Na, Young-Ok
Lee, Jae-Kyeong
Kho, Bo Gun
Kim, Tae-Ok
Kim, Yu-Il
Lim, Sung-Chul
Jeong, Sae-Hee
Kwon, Yong-Soo
Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
title Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
title_full Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
title_fullStr Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
title_full_unstemmed Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
title_short Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
title_sort major adverse cardiovascular events and hyperuricemia during tuberculosis treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653473/
https://www.ncbi.nlm.nih.gov/pubmed/37972037
http://dx.doi.org/10.1371/journal.pone.0294490
work_keys_str_mv AT shinhongjoon majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT yoonjoonyoung majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT nayoungok majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT leejaekyeong majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT khobogun majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT kimtaeok majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT kimyuil majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT limsungchul majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT jeongsaehee majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment
AT kwonyongsoo majoradversecardiovasculareventsandhyperuricemiaduringtuberculosistreatment